The past three decades have borne witness to many advances in the understanding of the
molecular biology and treatment of nasopharyngeal carcinoma (NPC), an Epstein–Barr virus …

PURPOSE To provide evidence-based recommendations for practicing physicians and
other health care providers on immunotherapy and biomarker testing for head and neck …

Gemcitabine-cisplatin (GP) chemotherapy is the standard first-line systemic treatment for
recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In this international, double …

Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor originating in the
nasopharynx and has a high incidence in Southeast Asia and North Africa. To develop these …

PURPOSE To provide evidence-based recommendations for practicing physicians and
other healthcare providers on the management of salivary gland malignancy. METHODS …

Background Patients with locoregionally advanced nasopharyngeal carcinoma have a high
risk of disease relapse, despite a high proportion of patients attaining complete clinical …

Importance Microbiota-tumor interactions have qualified microbiota as a promising
prognostic biomarker in various types of cancers. Although the nasopharynx acts as a …

Background The aim of this trial was to address whether elective ipsilateral upper-neck
irradiation (UNI) sparing the uninvolved lower neck provides similar regional relapse-free …

Although radiotherapy can promote antitumour immunity, the mechanisms underlying this
phenomenon remain unclear. Here, we demonstrate that the expression of the E3 ubiquitin …

Epstein–Barr virus (EBV) was the first tumor virus in humans. Nasopharyngeal carcinoma
(NPC) accounts for approximately 60% of the 200,000 new tumor cases caused by EBV …